ReviewBioengineering (Basel, Switzerland)2026
Piezo1 in Peripheral and Central Sensitisation: Implications for Chronic Pain.
Review in Bioengineering (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Piezo1 is an increasingly recognised mechanosensitive ion channel that transduces mechanical forces into electrical and biochemical signals and is expressed in peripheral sensory pathways as well as across multiple cell types within the central nervous system. Growing evidence indicates that Piezo1 contributes to nociceptive processing by influencing cellular excitability, inflammatory signalling, and neuron-glia interactions within nociceptive circuits. These actions position Piezo1 as an important contributor to amplified nociceptive transmission and circuit hyperexcitability, thereby potentially facilitating the transition from acute to chronic pain via several integrating mechanisms. In this context, Piezo1 may interact with other established mechanisms of chronic pain, including peripheral and central sensitisation and neuroinflammatory signalling, to help sustain persistent pain states. This review examines the potential roles of Piezo1 as a synergistic contributor to nociceptive hyperexcitability and considers how it may modulate nociceptive excitability, glial activation, and central sensitisation. Available findings support the view that Piezo1 participates in mechanotransduction and maladaptive plasticity relevant to chronic pain, although direct evidence for its cell-specific actions within spinal dorsal horn circuits remains limited. Piezo1 has also been implicated in tissue remodelling following spinal cord injury, suggesting that its therapeutic relevance may extend beyond pain signalling alone. Further studies will be required to clarify its mechanistic role in the mechanobiology of chronic pain and to evaluate the translational potential of targeting Piezo1 through pharmacological or genetic strategies for pain management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.